These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

714 related articles for article (PubMed ID: 15807715)

  • 21. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France.
    Bonnet F; Lewden C; May T; Heripret L; Jougla E; Bevilacqua S; Costagliola D; Salmon D; Chêne G; Morlat P;
    Scand J Infect Dis; 2005; 37(6-7):482-7. PubMed ID: 16089023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends and characteristics of all-cause mortality among HIV-infected inpatients during the HAART era (2006-2015) in Shanghai, China.
    Ji Y; Wang Z; Shen J; Chen J; Yang J; Qi T; Song W; Tang Y; Liu L; Shen Y; Zhang R; Lu H
    Biosci Trends; 2017 Mar; 11(1):62-68. PubMed ID: 28132999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers.
    Sabin CA; Smith CJ; Youle M; Lampe FC; Bell DR; Puradiredja D; Lipman MC; Bhagani S; Phillips AN; Johnson MA
    AIDS; 2006 Jan; 20(1):67-71. PubMed ID: 16327321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends of Cause of Death among Human Immunodeficiency Virus Patients and the Impact of Low CD4 Counts on Diagnosis to Death: a Retrospective Cohort Study.
    Kim Y; Kim SW; Chang HH; Kwon KT; Bae S; Hwang S
    J Korean Med Sci; 2020 Oct; 35(41):e355. PubMed ID: 33107229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality.
    Pinto AN; Grey P; Shaik A; Cooper DA; Kelleher AD; Petoumenos K
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):936-941. PubMed ID: 29901415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Trends in mortality and causes of death among persons with HIV infection, 1985-2004].
    Aldaz P; Castilla J; Moreno-Iribas C; Irisarri F; Floristán Y; Sola-Boneta J; Martínez-Artola V; Fernández-Jaúregui C; Dorronsoro I
    Enferm Infecc Microbiol Clin; 2007 Jan; 25(1):5-10. PubMed ID: 17261240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Causes of death and factors associated with early death among human immunodeficiency virus (HIV)-infected persons in Singapore: pre-highly active antiretroviral therapy (HAART) and Peri-HAART.
    Chow A; Tey J; Win MK; Leo YS
    Ann Acad Med Singap; 2012 Dec; 41(12):563-70. PubMed ID: 23303113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mortality and progression to AIDS after starting highly active antiretroviral therapy.
    van Sighem AI; van de Wiel MA; Ghani AC; Jambroes M; Reiss P; Gyssens IC; Brinkman K; Lange JM; de Wolf F;
    AIDS; 2003 Oct; 17(15):2227-36. PubMed ID: 14523280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.
    Sackoff JE; Hanna DB; Pfeiffer MR; Torian LV
    Ann Intern Med; 2006 Sep; 145(6):397-406. PubMed ID: 16983127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.
    Wada N; Jacobson LP; Cohen M; French A; Phair J; Muñoz A
    Am J Epidemiol; 2013 Jan; 177(2):116-25. PubMed ID: 23287403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective cohort study of children born to human immunodeficiency virus-infected mothers, 1985 through 1997: trends in the risk of vertical transmission, mortality and acquired immunodeficiency syndrome indicator diseases in the era before highly active antiretroviral therapy.
    Simpson BJ; Shapiro ED; Andiman WA
    Pediatr Infect Dis J; 2000 Jul; 19(7):618-24. PubMed ID: 10917219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries.
    Llibre JM; Revollo B; Vanegas S; Lopez-Nuñez JJ; Ornelas A; Marin JM; Santos JR; Marte P; Morera M; Zuluaga P; Tor J; Clotet B
    Scand J Infect Dis; 2013 Aug; 45(8):635-44. PubMed ID: 23547568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort.
    Croxford S; Kitching A; Desai S; Kall M; Edelstein M; Skingsley A; Burns F; Copas A; Brown AE; Sullivan AK; Delpech V
    Lancet Public Health; 2017 Jan; 2(1):e35-e46. PubMed ID: 29249478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study.
    Smit C; van den Berg C; Geskus R; Berkhout B; Coutinho R; Prins M
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):221-5. PubMed ID: 18223361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
    Gingues S; Gill MJ
    HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metropolitan social environments and pre-HAART/HAART era changes in mortality rates (per 10,000 adult residents) among injection drug users living with AIDS.
    Friedman SR; West BS; Pouget ER; Hall HI; Cantrell J; Tempalski B; Chatterjee S; Hu X; Cooper HL; Galea S; Des Jarlais DC
    PLoS One; 2013; 8(2):e57201. PubMed ID: 23437341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.
    Smith CJ; Ryom L; Weber R; Morlat P; Pradier C; Reiss P; Kowalska JD; de Wit S; Law M; el Sadr W; Kirk O; Friis-Moller N; Monforte Ad; Phillips AN; Sabin CA; Lundgren JD;
    Lancet; 2014 Jul; 384(9939):241-8. PubMed ID: 25042234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.